by Keishi Foecke | Jun 18, 2025 | Blog Post
As small and mid-sized biotech companies are facing increasing funding pressures, life sciences mergers and acquisitions (M&A) have emerged as an increasingly important mechanism to sustain innovation and advance new therapies. A recent analyst note highlighted...
by Keishi Foecke | Jun 11, 2025 | Blog Post
In comments to the Department of Justice (DOJ)’s Anticompetitive Regulations Task Force, PULSE urged DOJ and Federal Trade Commission (FTC) officials to revisit antitrust policies that are deterring pro-competitive life sciences mergers and acquisitions (M&A)....
by Keishi Foecke | Jun 5, 2025 | Blog Post
Amidst greater market uncertainty and a severely constrained initial public offering (IPO) environment, mergers and acquisitions (M&A) are serving as a critical “life raft” for investment, innovation and growth in America’s life sciences industry, reports Axios’...
by Keishi Foecke | May 21, 2025 | Blog Post
In response to the Office of Management and Budget’s recent Request for Information on Deregulation, PULSE urged federal regulators to revisit the latest changes to the Hart-Scott-Rodino (HSR) premerger notification rule. As noted in PULSE’s comments, the recent HSR...
by Keishi Foecke | May 14, 2025 | Blog Post
PULSE partners recently made their way to Capitol Hill to emphasize how mergers and acquisitions (M&A) are critical to advancing new breakthroughs to patients. Industry leaders from Biocom California, BioNJ, the Health Care Institute of New Jersey and Maryland...
by Keishi Foecke | May 7, 2025 | Blog Post
The U.S. life sciences industry is a key driver of economic growth and domestic manufacturing. American pharmaceutical manufacturers employ an estimated 291,000 employees, and for every one job in the pharmaceutical industry, four jobs are created in supporting...
